BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M

BIOCRYST PHARMACEUTICALS INC

2023-Q3 EPS reported -$0.87 revenue$238,011,000

Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.
Net loss $36.1M ($0.19/share) vs $42.5M ($0.23) in Q3 2022; operating cash use $16.5M (-43.9% yoy).
Full-year 2023 ORLADEYO revenue guidance reaffirmed at no less than $320M; peak revenue target $1B.
R&D expenses down 11% yoy to $46.9M due to program discontinuations; SG&A up 37% to $50.7M on ORLADEYO launch.
Cash and investments $399.2M at Sep 30, 2023; debt interest expense rose on Pharmakon facility.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOCRYST PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $86.7 million, net income $36.1 million, or $0.19 per share. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $86.7 million
Net income: $36.1 million, or $0.19 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in the investors section of the company website at www.biocryst.com. Third Quarter 2023 Financial Results For the three months ended September 30, 2023, total revenues were $86.7 million, compared to $75.8 million in the third quarter of 2022 (+14.4 percent y-o-y). The increase was primarily due to an increase in ORLADEYO net revenue of $19.7 million, partially

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-006627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.